Mechanistically, a low proportion of PD-1+ and CD8+ TILs co-expressed may underlie the low response rates to PD-1/PD-L1 inhibitors in EGFR-/ALK-positive NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.